EUVIMEDEUVIMED entdecken
Crossref

Acute kidney injury in patients included in early-phase oncology clinical trials, results of the AKITEP study

Matthieu Delaye, Paul Matte, Adrien Mouren, Julien Vibert, Kristi Beshiri, François Lion, Capucine Baldini, Rastislav Bahleda, Anas Gazzah, Kaissa Ouali, Antoine Hollebecque, Jean-Marie Michot und 11 weitere

European Journal of Cancer · 2026-06 · 242 · 116827

DOI: 10.1016/j.ejca.2026.116827 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Cancer, 2026-06. Verfasst von Matthieu Delaye und 22 weiteren Autor:innen. Beteiligte Einrichtung: Gustave Roussy Cancer Campus, Drug Development Department, Villejuif, France; Groupe de Recherche Interdisciplinaire Francophone en Onco-néphrologie …. Hauptthemen laut MEDLINE: Acute Kidney Injury, Neoplasms, Renal Insufficiency, Chronic. Die Arbeit nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND Acute kidney injury (AKI) and chronic kidney disease (CKD) are prevalent among patients with cancer and negatively impact prognosis. No data exists on the prevalence of AKI and CKD in early-phase oncology trials (EPT), risk factors and impact on patient outcomes. METHODS We conducted a retrospective study on all patients included in EPT in our institution between 01/2018 and 12/2023. Creatinine levels and estimated glomerular filtration rate (GFR), calculated using Cockroft-Gault (C-G), MDRD and CKD-EPI formulae, were collected at baseline and throughout the trial. The primary endpoint was the AKI rate. RESULTS We analyzed 2280 inclusions, corresponding to 2025 individual patients. Baseline MDRD< 60 mL/min was more prevalent in patients with urothelial, kidney or endometrial cancers (30%, 25% and 24% respectively). We found good concordance between CKD-EPI and MDRD (R=0.89), but low concordance between C-G and MDRD (R=0.57) or CKD-EPI (R=0.61). AKI occurred in 262 patients (12.9%). Occurrence of AKI was associated with cancer type (p = 0.0005) and age (p = 0.001) but not with lower baseline GFR, whatever the formula used. A higher baseline GFR was associated with a shorter time to treatment failure, defined as the time from treatment initiation to the end of treatment, regardless of the cause. CONCLUSION AKI was common in patients included in EPT but was not associated with baseline GFR in our study. Our results open the door to discussions about more accurate assessment of renal function in patients prior to inclusion in EPT, more flexible inclusion criteria, and more accurate monitoring of acute kidney injury during the trial.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acute Kidney InjuryNeoplasmsRenal Insufficiency, ChronicHumansFemaleRetrospective StudiesAgedGlomerular Filtration RateMiddle AgedMaleRisk FactorsCreatininePrevalenceClinical Trials as TopicAged, 80 and overPrognosis

Stichwörter der Autor:innen

Acute kidney injuryEarly-phase clinical trialsOncologyPrognosis

Substanzen

Creatinine

Autor:innen und Institutionen

  • Gustave Roussy Cancer Campus, Drug Development Department, Villejuif, France; Groupe de Recherche Interdisciplinaire Francophone en Onco-néphrologie (GRIFON), Paris, France.
  • Gustave Roussy Cancer Campus, Drug Development Department, Villejuif, France.
  • Gustave Roussy Cancer Campus, Direction de la Transformation Numérique et des Systèmes d'Information, Villejuif, France.
  • Gustave Roussy Cancer Campus, Drug Development Department, Villejuif, France; Laboratoire d'Immunomonitoring en Oncologie, INSERM US23, CNRS UMS 3655, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
  • Gustave Roussy Cancer Campus, Drug Development Department, Villejuif, France; Gustave Roussy Cancer Campus, Department of Medical Oncology, Villejuif, France; Gustave Roussy, INSERM Unité 981, Université Paris-Sud, Univ…
  • Gustave Roussy Cancer Campus, Drug Development Department, Villejuif, France. Electronic address: matthieu.roulleaux-dugage@gustaveroussy.fr.

Zitieren

APA

Delaye, M., Matte, P., Mouren, A., Vibert, J., Beshiri, K., Lion, F., Baldini, C., Bahleda, R., Gazzah, A., Ouali, K., Hollebecque, A., Michot, J. M., Smolenschi, C., Sakkal, M., Yeye, S., Fréon, K., Guibourt, M., Vincent, C., Postel-Vinay, S., …, & Roulleaux Dugage, M. (2026). Acute kidney injury in patients included in early-phase oncology clinical trials, results of the AKITEP study. European Journal of Cancer, 242, 116827. https://doi.org/10.1016/j.ejca.2026.116827

Vancouver

Delaye M, Matte P, Mouren A, Vibert J, Beshiri K, Lion F, et al. Acute kidney injury in patients included in early-phase oncology clinical trials, results of the AKITEP study. European Journal of Cancer. 2026;242:116827. doi:10.1016/j.ejca.2026.116827

BibTeX
@article{Delaye2026,
  author = {Delaye, Matthieu and Matte, Paul and Mouren, Adrien and Vibert, Julien and Beshiri, Kristi and Lion, François and Baldini, Capucine and Bahleda, Rastislav and Gazzah, Anas and Ouali, Kaissa and Hollebecque, Antoine and Michot, Jean-Marie and Smolenschi, Cristina and Sakkal, Madona and Yeye, Stevie and Fréon, Karine and Guibourt, Mélanie and Vincent, Charline and Postel-Vinay, Sophie and Marabelle, Aurélien and Loriot, Yohann and Massard, Christophe and Roulleaux Dugage, Matthieu},
  title = {Acute kidney injury in patients included in early-phase oncology clinical trials, results of the AKITEP study},
  journal = {European Journal of Cancer},
  year = {2026},
  volume = {242},
  pages = {116827},
  doi = {10.1016/j.ejca.2026.116827}
}
Kostenlos starten →